“Fresh ideas and multiple disciplines are needed to advance Temporomandibular Disorders (TMDs) research to improve patient care. The National Institutes of Health (NIH) provides approximately one third of all biomedical research funding in the United States and therefore, the interests and priorities of NIH Institutes and Centers can stimulate research interests and training programs throughout the country. TMDs are not the primary mission of any NIH Center or Institute.” (NAM report, Summary S-5)

NIH Grant Funding Opportunities

We invite you to view a list of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.

Table of Opportunities

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System

U44 Clinical Trial Optional

Posted: April 23, 2021

Open: July 10, 2021

Expires: April 06, 2024 

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

National Institute of Dental and Craniofacial Research (NIDCR)

NIDCR is interested in BPN Biologics development for craniofacial disorders and painful disorders of the orofacial region including temporomandibular joint disorders, trigeminal neuropathies, burning mouth syndrome, oral cancer pain, dental pain and other conditions. Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Awardees will be required to comply with the NIDCR Clinical Terms of Award for activities that involve human subjects research that have been determined by NIDCR to need additional oversight. Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

NIH Pain Consortium Grant Mechanism Webinar Series

The NIH Pain Consortium has developed a webinar series on NIH grant mechanisms in pain research across career stages (training, transition and independent stages).

The first webinar will be held on April 8, 2021, from 3:00-4:15 p.m. (U.S. Eastern time), and will focus on clinical mentoring grants. There will be nine more webinars on other grant types held over subsequent months; please see the schedule in the registration link.

The goal of this webinar series is to inform the pain research community of funding opportunities and other resources provided by the NIH. Each webinar will cover information on specific types of grant mechanisms and funding opportunities at individual career stages.

Each webinar will last approximately 1 hour and 15 minutes, and will consist of recorded presentations on specific types of grant mechanisms followed by a live question and answer session. NIH program staff from multiple NIH institutes and centers participating in the NIH Pain Consortium will be available for discussion and answering specific questions.

There is no cost for these webinars, but attendees must register in advance. The link to register can be found here. You may choose to register for any one of the sessions at this time, but we will also send out reminders as each one approaches.
The webinars will be recorded and after each one concludes it will be posted on the NIH Pain Consortium Website [https://www.painconsortium.nih.gov/] for those who are unable to participate live and for future reference.

Please consider joining to learn about the wide range of training and funding opportunities in pain research available from NIH, as well as policies and procedures on application preparation, submission, selection and award processes, and post-award monitoring/reviews.

Achieving Tissue Robustness Through Harnessing Immune Systems Plasticity

R21 Clinical Trial Not Allowed

R01 Clinical Trial Not Allowed

Posted: January 29, 2019

Open: May 16, 2019

Expires: May 8, 2022

This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.

Recent advances in understanding diseases and conditions involving DOC tissues – periodontitis, peri-implantitis, temporomandibular joint disorders (TMD), oral and oropharyngeal cancers, Sjögren’s Syndrome, and HIV/AIDS with its associated oral opportunistic infections, among others – demonstrate that the immune system significantly contributes to disease onset, progression, and persistence.

The Biomarkers Consortium

The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at Biomarkers Consortium. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.

The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.

Mechanisms Underlying the Contribution of Sleep Disturbances to Pain

R01 Clinical Trial Optional

R21 Clinical Trial Optional

Posted: February 28, 2019

Open: May 16, 2019

Expires: May 8, 2022

Information about the Foundation for NIH is available at http://www.fnih.org.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.